Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma
Abhishek Tripathi(Dana-Farber Cancer Institute), Lauren C. Harshman(Dana-Farber Cancer Institute)
Cited by 36
Related Papers
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma
|Nature Communications|2021|167
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
|Journal of Clinical Oncology|2019|147
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
|New England Journal of Medicine|2024|145
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
|Cancer Immunology Research|2018|136
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)
|Journal of Clinical Oncology|2020|105